



## Post Authorisation Assessments

### Suvaxyn MH-One Emulsion for Injection for Pigs

Vm 42058/5123

•	18 May 2024	Alignment of the SPC/QRD text with the newest EU version 9.0 QRD template and GB National SPC/QRD template.
•	18 May 2024	Change in the reagents of the in-process assay of the active substance.
•	22 September 2021	Replacement to a test procedure for the finished product.
•	25 October 2019	Change in the address of the marketing authorisation holder from Zoetis UK Limited, 5th Floor, 6 St. Andrew Street, London, EC4A 3AE to Zoetis UK Limited, 1st Floor, Birchwood Building, Springfield Drive, Leatherhead, Surrey, KT22 7LP.
•	16 April 2019	Addition of a supplier of packaging components.
•	25 September 2018	Change in the contact details of the QPPV of an existing pharmacovigilance system as described in the DDPS.
•	04 July 2018	Repeat Use application to add 3 new member states
•	15 February 2017	<p>Minor change to an approved test procedure for the intermediate used in the manufacturing process of the active substance.</p> <p>Deletion of a non-significant specification parameter of the finished product.</p> <p>Deletion of a non-significant in-process test applied during the manufacture of the active substance.</p> <p>Addition of a new in-process test and limit applied during the manufacture of the active substance.</p> <p>Deletion of a non-significant in-process test applied during the manufacture of the finished product</p> <p>Changes to a test procedure for the active substance.</p> <p>Changes to a test procedure for the active substance.</p> <p>Change to a test procedure for the finished product.</p> <p>Change in the manufacturing process of the finished product.</p> <p>Change in the manufacturing process of the finished product.</p> <p>Update of specification parameters.</p> <p>Minor change in the manufacturing process of the active substance.</p> <p>Submission of a revised Part 2 dossier.</p>
•	02 February 2016	Change in name of a manufacturer of the active substance.
•	12 June 2015	To extend the shelf-life of the finished product to 24 months.
•	30 April 2015	Change in the QPPV contact details.

•	10 April 2015	Update to the product dossier. Change of site for testing starting materials of biological origin. Change in test procedure for testing starting materials of biological origin.
•	22 January 2015	Transfer of test location for a test procedure.
•	16 January 2015	Removal of a test procedure for the finished product.
•	16 October 2014	To increase the shelf-life of the 50-dose and 125-dose presentations in HDPE bottles, from 12 months to 15 months. Change in the specification parameters/limits of the finished product.
•	30 May 2014	Change to two test procedures.
•	09 October 2013	Change of MAH in Austria, Belgium, France, Luxembourg only.
•	09 October 2013	Change in the name of manufacturer of the active substance. Changes in the name of manufacturer of the finished product. Change of QPPV contact details.
•	28 August 2013	Renewal.
•	07 January 2013	To tighten the specification limits. To reduce the minimum age for vaccine from 21 days to 7 days.
•	27 December 2012	Variation to reduce the onset of immunity of the vaccine, from 4 weeks to 2 weeks after the primary vaccination scheme.
•	15 August 2011	To change the name of the manufacturer for blending, filling, assembly, batch release, final product testing and labelling.
•	15 August 2011	To change the name and/or address of a manufacturer of the finished product, including quality control sites.
•	15 August 2011	To change the name and/or address of a manufacturer of the finished product, including quality control sites.
•	11 March 2011	To change the MAH address of the local office in Poland.
•	16 June 2010	To change the MAH and distributor from Fort Dodge Animal Health Ltd to Pfizer Limited.